Results 141 to 150 of about 41,075 (183)

A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity. [PDF]

Front Immunol
Etna MP, Fuoco C, Severa M, Ricci D, Sinigaglia A, Lucca C, Cairo G, Bottazzi B, Garlanda C, Palamara AT, Barzon L, Gargioli C, Coccia EM.   +12 more
europepmc   +1 more source

Effectiveness of COVID-19 Vaccination in Reducing Severity Among SARS-CoV-2 Infected Patients: A Prospective Study From Iraq. [PDF]

Health Sci Rep
Al-Obaidi AH, Ibrahim MM, Al-Qaseer AHAM.   +2 more
europepmc   +1 more source

Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids. [PDF]

Nat Biomed Eng
Zhao Y, Li R, Liu P, Wang J, Cui Y, Ma Y, Cao Z, Cui M, Luozhong S, Wagner E, Laflin A, Ding Y, Hu Y, Tian Z, Tang C, Cai S, Young H, Liu D, Gu W, Bailey S, Jiang S.   +20 more
europepmc   +1 more source

Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination. [PDF]

J Diabetes Metab Disord
Van Baal L, Tan S, Fuhrer D, Reinold J, Dittmer U, Fiedler M.   +5 more
europepmc   +1 more source

Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study. [PDF]

Hum Vaccin Immunother
Smolinski M, Chew JL, Constantinescu C, Buchan CA, Burton C, Carignan A, Castellucci LA, Suresh S, McConnell A, Morris SK, Naus M, Pernica JM, Pham-Huy A, Piche-Renaud PP, Sadarangani M, Top KA, Cowan J, Special Immunization Clinic Network investigators.   +17 more
europepmc   +1 more source

Dermatomyositis with Anti-MDA5 Autoantibodies After SARS-CoV-2 mRNA Vaccination Treated with Tofacitinib: Integrating Literature Evidence and a Novel Observation. [PDF]

Antibodies (Basel)
Benucci M, Cioffi E, Li Gobbi F, Cassarà EAM, Terenzi R, Russo E, Grossi V, Lari B, Infantino M, Manfredi M.   +9 more
europepmc   +1 more source

<i>CMTM8</i> variants influence BNT162b2 COVID-19 vaccination response by regulating granulocytic/polymorphonuclear myeloid-derived suppressor cell activity. [PDF]

Front Immunol
Testori A, Mulas A, Marongiu M, Orrù V, Lobina M, Piras MG, Lutzu E, Curreli N, Politi C, Mobrici M, Iervasi G, Corda D, De Felice M, Testa A, Devoto M, Steri M, Fiorillo E, SerGenCovid-19 Investigators.   +17 more
europepmc   +1 more source

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study. [PDF]

PLoS Med
Kawamoto A, Hashida M, Ishida K, Furihata K, Ota A, Takahashi K, Sakakibara S, Nakano T, Takeshita F.   +8 more
europepmc   +1 more source

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study. [PDF]

Vaccines (Basel)
Barbosa Beloni Lirio M, Machado KLLL, Assis Martins-Filho O, Miyamoto ST, Gurtler Pinheiro de Oliveira Y, Vieira Serrano É, Geraldo Mill J, Rosemarie Lallemand Tapia K, Baptista Ferreira L, Ribeiro de Oliveira J, Gouvea MDPG, Rodrigues Aguiar LG, Souza BO, Cruz VA, Xavier RM, Teixeira Carvalho A, de Souza VA, Ferreira GA, Monticielo OA, Neto ETDR, Sato EI, Pileggi GS, Valim V.   +22 more
europepmc   +1 more source

Vaccine Platform-Dependent Differential Impact on Microbiome Diversity: Potential Advantages of Protein Subunit Vaccines. [PDF]

Vaccines (Basel)
Seong H, Yoon JG, Nham E, Choi YJ, Noh JY, Cheong HJ, Kim WJ, Lim S, Song JY.   +8 more
europepmc   +1 more source